Tumor dormancy and ageing: Understanding cancer recurrence

Abstract

Cancer recurrence remains a leading cause of mortality in patients with solid tumors. Early disseminated tumor cells (DTCs), which seed distant organs during the initial stage of tumor progression, are widely recognized as an important source of late metastatic relapse. Tumor cell dormancy, a reversible but prolonged non-proliferative state, enables DTCs to survive in metastatic tissues for years or even decades before re-entering the cell cycle and giving rise to overt metastases. Accumulating evidence indicates that dormancy is regulated by both cell-intrinsic mechanisms, such as epigenetic reprogramming and metabolic adaptation, and extrinsic cues from the tissue microenvironment. Among these extrinsic regulators, ageing has emerged as a critical determinant of DTC fate by profoundly remodeling tissue microenvironments through cellular senescence, chronic inflammation, extracellular matrix (ECM) remodeling, vascular dysfunction, stromal metabolic rewiring, and immune dysregulation. These ageing-associated alterations progressively erode dormancy-supportive niches, thereby leading to metastatic reactivation. In this Review, we summarize the molecular mechanisms governing tumor dormancy and discuss how ageing-associated microenvironmental remodeling contributes to the reactivation of dormant DTCs. We highlight the roles of the senescence-associated secretory phenotype (SASP), ECM remodeling, vascular deterioration, and organ-specific stromal ageing in regulating the maintenance and exit of tumor dormancy. We also discuss emerging translational opportunities, including dormancy-reinforcing therapies, senolytic strategies, liquid biopsy-based surveillance, and advanced experimental platforms such as single-cell and spatial technologies. Collectively, this Review provides a conceptual framework for understanding how ageing progressively modulates tumor dormancy and highlights potential strategies to prevent late metastatic recurrence.

Keywords

Ageing / tumor dormancy / disseminated tumor cells / cellular senescence / tumor microenvironment / cancer recurrence

1 Acknowledgements

The authors declare that Claude Sonnet 4.6 was used solely for language polishing during the manuscript preparation process. The authors take full responsibility for the integrity, originality, and accuracy of the work.

2 Authors contribution

Wu F: Writing-original draft.

Meng Y, Cao M, Zhang J: Writing-review & editing.

Wu Y, Tang X: Conceptualization, writing-review & editing.

3 Conflicts of interest

The authors declare no conflicts of interest.

4 Ethical approval

Not applicable.

5 Consent to participate

Not applicable.

6 Consent for publication

Not applicable.

7 Availability of data and materials

Not applicable.

Funding

This study was supported by the Fundamental Research Funds for the Central Universities (Grant Nos. 521119200099, 541109030051 and Ageing Cancer Res Treat. 2026;3:202628 | https://doi.org/10.70401/acrt.2026.0030 Page 10 of 15 531119200268).

References

[1] Fane M, Weeraratna AT. How the ageing microenvironment influences tumour progression. Nat Rev Cancer. 2020; 20(2):89-106.

[2] DeMichele A, Clark AS, Shea E, Bayne LJ, Sterner CJ, Rohn K, et al. Targeting dormant tumor cells to prevent recurrent breast cancer: A randomized phase 2 trial. Nat Med. 2025; 31(10):3464-3474.

[3] Fane ME, Chhabra Y, Alicea GM, Maranto DA, Douglass SM, Webster MR, et al. Stromal changes in the aged lung induce an emergence from melanoma dormancy. Nature. 2022; 606(7913):396-405.

[4] Harper EI, Weeraratna AT. A wrinkle in TIME: How changes in the aging ECM drive the remodeling of the tumor immune microenvironment. Cancer Discov. 2023; 13(9):1973-1981.

[5] Giancotti FG. Mechanisms governing metastatic dormancy and reactivation. Cell. 2013; 155(4):750-764.

[6] Willis RA. The spread of tumours in the human body. 1st ed. & A. Churchil; 1934:

[7] Hadfield G. The dormant cancer cell. Br Med J. 1954; 2(4888):607-610.

[8] Peng P, Qin S, Li L, He Z, Li B, Nice EC, et al. Epigenetic remodeling under oxidative stress: Mechanisms driving tumor metastasis. MedComm-Oncology. 2024; 3(4):e70000.

[9] Tao L, Zhou Y, Luo Y, Qiu J, Xiao Y, Zou J, et al. Epigenetic regulation in cancer therapy: From mechanisms to clinical advances. MedComm-Oncology. 2024; 3(1):e59.

[10] Liang Y, Chen WM, Zhang Y, Li L. Remodeling the tumor dormancy ecosystem to prevent recurrence and metastasis. Sig Transduct Target Ther. 2026; 11(1):1.

[11] Tiwary K, Bravo-Cordero JJ.Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance. Mol Oncol. 2026.

[12] Easwaran H, Weeraratna AT. Unravelling the genetics and epigenetics of the ageing tumour microenvironment in cancer. Nat Rev Cancer. 2025; 25(11):828-847.

[13] Min HY, Lee HY. Cellular dormancy in cancer: Mechanisms and potential targeting strategies. Cancer Res Treat. 2023; 55(3):720-736.

[14] Ghajar CM, Peinado H, Mori H, Matei IR, Evason KJ, Brazier H, et al. The perivascular niche regulates breast tumour dormancy. Nat Cell Biol. 2013; 15(7):807-817.

[15] Correia AL, Guimaraes JC, Auf der Maur P, de Silva D, Trefny MP, Okamoto R, et al.Hepatic stellate cells suppress NK cell-sustained breast cancer dormancy. Nature. 2021; 594(7864):566-571.

[16] Saleh T, Gewirtz DA. Considering therapy-induced senescence as a mechanism of tumour dormancy contributing to disease recurrence. Br J Cancer. 2022; 126(10):1363-1365.

[17] Saleh T, Tyutyunyk-Massey L, Gewirtz DA. Tumor cell escape from therapy-induced senescence as a model of disease recurrence after dormancy. Cancer Res. 2019; 79(6):1044-1046.

[18] Duy C, Li M, Teater M, Meydan C, Garrett-Bakelman FE, Lee TC, et al. Chemotherapy induces senescence-like resilient cells capable of initiating AML recurrence. Cancer Discov. 2021; 11(6):1542-1561.

[19] Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 2007; 7(11):834-846.

[20] Sosa MS, Parikh F, Maia AG, Estrada Y, Bosch A, Bragado P, et al. NR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmes. Nat Commun. 2015; 6:6170.

[21] Borgen E, Rypdal MC, Sosa MS, Renolen A, Schlichting E, Lønning PE, et al. NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients. Breast Cancer Res. 2018; 20(1):120.

[22] Vera-Ramirez L, Vodnala SK, Nini R, Hunter KW, Green JE. Autophagy promotes the survival of dormant breast cancer cells and metastatic tumour recurrence. Nat Commun. 2018; 9(1):1944.

[23] Nobre AR, Dalla E, Yang J, Huang X, Wullkopf L, Risson E, et al. ZFP281 drives a mesenchymal-like dormancy program in early disseminated breast cancer cells that prevents metastatic outgrowth in the lung. Nat Cancer. 2022; 3(10):1165-1180.

[24] Braun S, Pantel K, Müller P, Janni W, Hepp F, Kentenich CRM, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med. 2000; 342(8):525-533.

[25] Hartkopf AD, Brucker SY, Taran FA, Harbeck N, von Au A, Naume B, et al. Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis. Eur J Cancer. 2021; 154:128-137.

[26] Nobre AR, Risson E, Singh DK, di Martino JS, Cheung JF, Wang J, et al. Bone marrow NG2⁺/Nestin⁺ mesenchymal stem cells drive DTC dormancy via TGF-β2. Nat Cancer. 2021; 2(3):327-339.

[27] Di Martino JS, Nobre AR, Mondal C, Taha I, Farias EF, Fertig EJ, et al. A tumor-derived type III collagen-rich ECM niche regulates tumor cell dormancy. Nat Cancer. 2022; 3(1):90-107.

[28] Albrengues J, Shields MA, Ng D, Park CG, Ambrico A, Poindexter ME, et al. Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science. 2018; 361(6409):eaao4227.

[29] Hu J, Sánchez-Rivera FJ, Wang Z, Johnson GN, Ho YJ, Ganesh K, et al. STING inhibits the reactivation of dormant metastasis in lung adenocarcinoma. Nature. 2023; 616(7958):806-813.

[30] Dai J, Cimino PJ, Gouin KH 3rd, Grzelak CA, Barrett A, Lim AR, et al. Astrocytic laminin-211 drives disseminated breast tumor cell dormancy in brain. Nat Cancer. 2022; 3(1):25-42.

[31] Coppé JP, Patil CK, Rodier F, Sun Y, Muñoz DP, Goldstein J, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p 53 tumor suppressor. PLoS Biol. 2008; 6(12):2853-2868.

[32] Zhou L, DeMarco KD, Murphy KC, Wu Z, Li J, Johnson C, et al. p21-positive senescent stromal cells promote prostate cancer immune suppression and progression that can be reversed by senolytic therapy. Cancer Discov. 2026; 16(3):571-591.

[33] Fan G, Yu B, Tang L, Zhu R, Chen J, Zhu Y, et al. TSPAN8⁺ myofibroblastic cancer-associated fibroblasts promote chemoresistance in patients with breast cancer. Sci Transl Med. 2024; 16(741):eadj5705.

[34] Campos C, López N, Pera A, Gordillo JJ, Hassouneh F, Tarazona R, et al. Expression of NKp30, NKp46 and DNAM-1 activating receptors on resting and IL-2 activated NK cells from healthy donors according to CMV-serostatus and age. Biogerontology. 2015; 16(5):671-683.

[35] Liu Q, Li J, Sun X, Lin J, Yu Z, Xiao Y, et al. Immunosenescence and cancer: Molecular hallmarks, tumor microenvironment remodeling, and age-specific immunotherapy challenges. J Hematol Oncol. 2025; 18(1):81.

[36] Barkan D, El Touny LH, Michalowski AM, Smith JA, Chu I, Davis AS, et al. Metastatic growth from dormant cells induced by a col-I-enriched fibrotic environment. Cancer Res. 2010; 70(14):5706-5716.

[37] Carlson P, Dasgupta A, Grzelak CA, Kim J, Barrett A, Coleman IM, et al. Targeting the perivascular niche sensitizes disseminated tumour cells to chemotherapy. Nat Cell Biol. 2019; 21(2):238-250.

[38] Franceschi C, Bonafè M, Valensin S, Olivieri F, De Luca M, Ottaviani E, et al. Inflamm-aging: An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000; 908(1):244-254.

[39] López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. Cell. 2023; 186(2):243-278.

[40] López-Otín C, Pietrocola F, Roiz-Valle D, Galluzzi L, Kroemer G. Meta-hallmarks of aging and cancer. Cell Metab. 2023; 35(1):12-35.

[41] Reynolds LE, Maallin S, Haston S, Martinez-Barbera JP, Hodivala-Dilke KM, Pedrosa AR, et al. Effects of senescence on the tumour microenvironment and response to therapy. FEBS J. 2024; 291(11):2306-2319.

[42] Dong Z, Luo Y, Yuan Z, Tian Y, Jin T, Xu F, et al. Cellular senescence and SASP in tumor progression and therapeutic opportunities. Mol Cancer. 2024; 23(1):181.

[43] Coppé JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: The dark side of tumor suppression. Annu Rev Pathol Mech Dis. 2010; 5:99-118.

[44] Hüser L, Chhabra Y, Gololobova O, Wang V, Liu G, Dixit A, et al. Aged fibroblast-derived extracellular vesicles promote angiogenesis in melanoma. Cell Rep. 2024; 43(9):114721.

[45] Zhang L, Wu X, Feng Y, Zheng L, Jian J. Selenium donors inhibits osteoclastogenesis through inhibiting IL-6 and plays a pivotal role in bone metastasis from breast cancer. Toxicol Res. 2020; 9(4):544-551.

[46] Luo X, Fu Y, Loza AJ, Murali B, Leahy KM, Ruhland MK, et al. Stromal-initiated changes in the bone promote metastatic niche development. Cell Rep. 2016; 14(1):82-92.

[47] Di GH, Liu Y, Lu Y, Liu J, Wu C, Duan HF, et al. IL-6 secreted from senescent mesenchymal stem cells promotes proliferation and migration of breast cancer cells. PLoS One. 2014; 9(11):e113572.

[48] Ruhland MK, Loza AJ, Capietto AH, Luo X, Knolhoff BL, Flanagan KC, et al. Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis. Nat Commun. 2016; 7:11762.

[49] Liang Y, Chen WM, Zhang Y, Li L. Remodeling the tumor dormancy ecosystem to prevent recurrence and metastasis. Sig Transduct Target Ther. 2026; 11(1):1.

[50] Faget DV, Ren Q, Stewart SA. Unmasking senescence: Context-dependent effects of SASP in cancer. Nat Rev Cancer. 2019; 19(8):439-453.

[51] Chiu FY, Kvadas RM, Mheidly Z, Shahbandi A, Jackson JG. Could senescence phenotypes strike the balance to promote tumor dormancy? Cancer Metastasis Rev. 2023; 42(1):143-160.

[52] DeLuca VJ, Saleh T. Insights into the role of senescence in tumor dormancy: Mechanisms and applications. Cancer Metastasis Rev. 2023; 42(1):19-35.

[53] Kirkland JL. Tumor dormancy and disease recurrence. Cancer Metastasis Rev. 2023; 42(1):9-12.

[54] Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AHFM, Schlegelberger B, et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature. 2005; 436(7051):660-665.

[55] Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M, et al. Senescence in premalignant tumours. Nature. 2005; 436(7051):642.

[56] Luo J, Sun T, Liu Z, Liu Y, Liu J, Wang S, et al. Persistent accumulation of therapy-induced senescent cells: An obstacle to long-term cancer treatment efficacy. Int J Oral Sci. 2025; 17(1):59.

[57] He D, Wu Q, Tian P, Liu Y, Jia Z, Li Z, et al. Chemotherapy awakens dormant cancer cells in lung by inducing neutrophil extracellular traps. Cancer Cell. 2025; 43(9):1622-1636.e7.

[58] Zhu H, Blake S, Kusuma FK, Pearson RB, Kang J, Chan KT, et al. Oncogene-induced senescence: From biology to therapy. Mech Ageing Dev. 2020; 187:111229.

[59] Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 1997; 88(5):593-602.

[60] Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol. 2001; 2(10):731-737.

[61] Gil J, Peters G. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: All for one or one for all. Nat Rev Mol Cell Biol. 2006; 7(9):667-677.

[62] Kuilman T, Michaloglou C, Vredeveld LCW, Douma S, van Doorn R, Desmet CJ, et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell. 2008; 133(6):1019-1031.

[63] Yücel AD, Gladyshev VN. Systemic epigenetic dysregulation as a driver of ageing and a therapeutic target. Nat Rev Mol Cell Biol. 2026; 27(7):528-542.

[64] Miwa S, Kashyap S, Chini E, von Zglinicki T. Mitochondrial dysfunction in cell senescence and aging. J Clin Investig. 2022; 132(13):e158447.

[65] Tomtheelnganbee E, Sah P, Sharma R. Mitochondrial function and nutrient sensing pathways in ageing: Enhancing longevity through dietary interventions. Biogerontology. 2022; 23(6):657-680.

[66] Hruby AJ, Higuchi-Sanabria R. Mitochondrial dysfunction in cellular senescence: A bridge to neurodegenerative disease. NPJ Aging. 2025; 11(1):99.

[67] Kaur A, Ecker BL, Douglass SM, Kugel CH 3rd, Webster MR, Almeida FV, et al. Remodeling of the collagen matrix in aging skin promotes melanoma metastasis and affects immune cell motility. Cancer Discov. 2019; 9(1):64-81.

[68] Ecker BL, Kaur A, Douglass SM, Webster MR, Almeida FV, Marino GE, et al. Age-related changes in HAPLN1 increase lymphatic permeability and affect routes of melanoma metastasis. Cancer Discov. 2019; 9(1):82-95.

[69] Marino-Bravante GE, Carey AE, Hüser L, Dixit A, Wang V, Kaur A, et al. Age-dependent loss of HAPLN1 erodes vascular integrity via indirect upregulation of endothelial ICAM1 in melanoma. Nat Aging. 2024; 4(3):350-363.

[70] Fane ME, Chhabra Y, Alicea GM, Maranto DA, Douglass SM, Webster MR, et al. Author Correction: Stromal changes in the aged lung induce an emergence from melanoma dormancy. Nature. 2025; 638(8051):E31.

[71] Demaria M, O’Leary MN, Chang J, Shao L, Liu S, Alimirah F, et al. Cellular senescence promotes adverse effects of chemotherapy and cancer relapse. Cancer Discov. 2017; 7(2):165-176.

[72] Chen J, Sivan U, Tan SL, Lippo L, de Angelis J, Labella R, et al. High-resolution 3D imaging uncovers organ-specific vascular control of tissue aging. Sci Adv. 2021; 7(6):eabd7819.

[73] Seals DR, Jablonski KL, Donato AJ. Aging and vascular endothelial function in humans. Clin Sci. 2011; 120(9):357-375.

[74] Scioli M, Bielli A, Arcuri G, Ferlosio A, Orlandi A. Ageing and microvasculature. Vasc Cell. 2014; 6(1):19.

[75] Ogle ME, Corstvet JL, Vayalakkara RK, Fernández FM, Temenoff JS. Senescence-induced lipidome alterations in mesenchymal stromal cells. J Proteome Res. 2025; 24(12):5986-5994.

[76] Wu H, Han Y, Rodriguez Sillke Y, Deng H, Siddiqui S, Treese C, et al. Lipid droplet‐dependent fatty acid metabolism controls the immune suppressive phenotype of tumor‐associated macrophages. EMBO Mol Med. 2019; 11(11):e10698.

[77] Ge M, Sun S, Chen W, Xu Z, Kang D, Wang Z, et al. Senescent fibroblasts drive CD8⁺ T cell dysfunction in colorectal cancer via CD36-mediated lipid transfer and peroxidation. J Transl Med. 2026; 24(1):310.

[78] Vaena S, Chakraborty P, Lee HG, Janneh AH, Kassir MF, Beeson G, et al. Aging-dependent mitochondrial dysfunction mediated by ceramide signaling inhibits antitumor T cell response. Cell Rep. 2021; 35(5):109076.

[79] Sonar SA, Bhat R, Thompson HL, Coplen CP, Uhrlaub JL, Jergovic M, et al. Age-related oxidative stress and mitochondrial dysfunction in lymph node stromal cells limit the peripheral T cell homeostatic maintenance and function. Aging Cell. 2025; 24(8):e70100.

[80] Zhang G, Wang Y, Lin J, Wang B, Mohsin A, Cheng Z, et al. Biological activity reduction and mitochondrial and lysosomal dysfunction of mesenchymal stem cells aging in vitro. Stem Cell Res Ther. 2022; 13(1):411.

[81] Dou X, Fu Q, Long Q, Liu S, Zou Y, Fu D, et al. PDK4-dependent hypercatabolism and lactate production of senescent cells promotes cancer malignancy. Nat Metab. 2023; 5(11):1887-1910.

[82] Barilani M, Lovejoy C, Piras R, Abramov AY, Lazzari L, Angelova PR, et al. Age-related changes in the energy of human mesenchymal stem cells. J Cell Physiol. 2022; 237(3):1753-1767.

[83] Alicea GM, Rebecca VW, Goldman AR, Fane ME, Douglass SM, Behera R, et al. Changes in aged fibroblast lipid metabolism induce age-dependent melanoma cell resistance to targeted therapy via the fatty acid transporter FATP₂. Cancer Discov. 2020; 10(9):1282-1295.

[84] Li Z, Sun C, Qin Z. Metabolic reprogramming of cancer-associated fibroblasts and its effect on cancer cell reprogramming. Theranostics. 2021; 11(17):8322-8336.

[85] Wu D, Zhuo L, Wang X. Metabolic reprogramming of carcinoma-associated fibroblasts and its impact on metabolic heterogeneity of tumors. Semin Cell Dev Biol. 2017; 64:125-131.

[86] Zhang F, Guo J, Yu S, University CM, Zheng Y, et al. Cellular senescence and metabolic reprogramming: Unraveling the intricate crosstalk in the immunosuppressive tumor microenvironment. Cancer Commun. 2024; 44(9):929-966.

[87] Puente-Cobacho B, Varela-López A, Quiles JL, Vera-Ramirez L. Involvement of redox signalling in tumour cell dormancy and metastasis. Cancer Metastasis Rev. 2023; 42(1):49-85.

[88] Bhagat TD, Von Ahrens D, Dawlaty M, Zou Y, Baddour J, Achreja A, et al. Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblasts. Elife. 2019; 8:e50663.

[89] Ippolito L, Comito G, Parri M, Iozzo M, Duatti A, Virgilio F, et al. Lactate rewires lipid metabolism and sustains a metabolic-epigenetic axis in prostate cancer. Cancer Res. 2022; 82(7):1267-1282.

[90] Lyssiotis CA, Kimmelman AC. Metabolic interactions in the tumor microenvironment. Trends Cell Biol. 2017; 27(11):863-875.

[91] Tinaburri L, Valente C, Teson M, Minafò YA, Cordisco S, Guerra L, et al. The secretome of aged fibroblasts promotes EMT-like phenotype in primary keratinocytes from elderly donors through BDNF-TrkB axis. J Investig Dermatol. 2021; 141(4):1052-1062.e12.

[92] Baker DJ, Childs BG, Durik M, Wijers ME, Sieben CJ, Zhong J, et al. Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature. 2016; 530(7589):184-189.

[93] Wang Y, Ding Y, Guo N, Wang S. MDSCs: Key criminals of tumor pre-metastatic niche formation. Front Immunol. 2019; 10:172.

[94] Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021; 21(8):485-498.

[95] Sceneay J, Chow MT, Chen A, Halse HM, Wong CS, Andrews DM, et al. Primary tumor hypoxia recruits CD11b⁺/Ly6C^med/Ly6G⁺ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche. Cancer Res. 2012; 72(16):3906-3911.

[96] Chen ACY, Jaiswal S, Martinez D, Yerinde C, Ji K, Miranda V, et al. The aged tumor microenvironment limits T cell control of cancer. Nat Immunol. 2024; 25(6):1033-1045.

[97] Liu Z, Zuo L, Zhou Z, Liu S, Ba Y, Zuo A, et al. Targeting immunosenescence for improved tumor immunotherapy. MedComm. 2024; 5(11):e777.

[98] Huynh J, Nishimura N, Rana K, Peloquin JM, Califano JP, Montague CR, et al. Age-related intimal stiffening enhances endothelial permeability and leukocyte transmigration. Sci Transl Med. 2011; 3(112):e3002761.

[99] Yang L, Froio RM, Sciuto TE, Dvorak AM, Alon R, Luscinskas FW. ICAM-1 regulates neutrophil adhesion and transcellular migration of TNF-alpha-activated vascular endothelium under flow. Blood. 2005; 106(2):584-592.

[100] Ma L, Guo H, Zhao Y, Liu Z, Wang C, Bu J, et al. Liquid biopsy in cancer current: Status, challenges and future prospects. Sig Transduct Target Ther. 2024; 9(1):336.

[101] Moqri M, Herzog C, Poganik JR, Justice J, Belsky DW, Higgins-Chen A, et al. Biomarkers of aging for the identification and evaluation of longevity interventions. Cell. 2023; 186(18):3758-3775.

[102] Ying K, Paulson S, Eames A, Tyshkovskiy A, Li S, Eynon N, et al. A unified framework for systematic curation and evaluation of aging biomarkers. Nat Aging. 2025; 5(11):2323-2339.

[103] Lin D, Shen L, Luo M, Zhang K, Li J, Yang Q, et al. Circulating tumor cells: Biology and clinical significance. Sig Transduct Target Ther. 2021; 6:404.

[104] Gao Q, Chen K, Gao L, Zheng Y, Yang YG. Thrombospondin-1 signaling through CD47 inhibits cell cycle progression and induces senescence in endothelial cells. Cell Death Dis. 2016; 7(9):e2368.

[105] Lawson MA, McDonald MM, Kovacic N, Hua Khoo W, Terry RL, Down J, et al. Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. Nat Commun. 2015; 6:8983.

[106] Turrell FK, Orha R, Guppy NJ, Gillespie A, Guelbert M, Starling C, et al. Age-associated microenvironmental changes highlight the role of PDGF-C in ER⁺ breast cancer metastatic relapse. Nat Cancer. 2023; 4(4):468-484.

[107] Crist SB, Nemkov T, Dumpit RF, Dai J, Tapscott SJ, True LD, et al. Unchecked oxidative stress in skeletal muscle prevents outgrowth of disseminated tumour cells. Nat Cell Biol. 2022; 24(4):538-553.

[108] Liu N, Wu J, Deng E, Zhong J, Wei B, Cai T, et al. Reversing immunosenescence with senolytics to enhance tumor immunotherapy. medRxiv [Preprint]. 2024.

[109] Jain SS, Burton Sojo G, Sun H, Friedland BN, McNamara ME, Schmidt MO, et al. The role of aging and senescence in immune checkpoint inhibitor response and toxicity. IJMS. 2024; 25(13):7013.

[110] Khalil BD, Sanchez R, Rahman T, Rodriguez-Tirado C, Moritsch S, Martinez AR, et al. An NR2F1-specific agonist suppresses metastasis by inducing cancer cell dormancy. J Exp Med. 2022; 219:e20210836.

[111] Singh DK, Carcamo S, Farias EF, Hasson D, Zheng W, Sun D, et al. 5-Azacytidine- and retinoic-acid-induced reprogramming of DCCs into dormancy suppresses metastasis via restored TGF-β-SMAD4 signaling. Cell Rep. 2023; 42(6):112560.

[112] Hong T, Hogger AC, Wang D, Pan Q, Gansel J, Engleitner T, et al. CDK4/6 inhibition initiates cell cycle arrest by nuclear translocation of RB and induces a multistep molecular response. Cell Death Discov. 2024; 10(1):453.

[113] Cetin B, Wabl CA, Gumusay O. CDK4/ 6 inhibitors: Mechanisms of resistance and potential biomarkers of responsiveness in breast cancer. Future Oncol. 2022; 18(9):1143-1157.

[114] Goddard ET, Linde MH, Srivastava S, Klug G, Shabaneh TB, Iannone S, et al. Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies. Cancer Cell. 2024; 42(1):119-134.e12.

[115] Zhang P, Zhang G, Wan X. Challenges and new technologies in adoptive cell therapy. J Hematol Oncol. 2023; 16(1):97.

[116] Yao P, Liu YG, Huang G, Hao L, Wang R. The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: Current state, challenges and emerging therapeutic advances. Exp Hematol Oncol. 2024; 13(1):118.

[117] Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1):17-48.

[118] Henry CJ, DeGregori J. Modelling the ageing dependence of cancer evolutionary trajectories. Nat Rev Cancer. 2025; 25(10):757-780.

[119] Marongiu F, DeGregori J. The sculpting of somatic mutational landscapes by evolutionary forces and their impacts on aging-related disease. Mol Oncol. 2022; 16(18):3238-3258.

[120] Anczuków O, Airhart S, Chuang JH, Coussens LM, Kuchel GA, Korstanje R, et al. Challenges and opportunities for modeling aging and cancer. Cancer Cell. 2023; 41(4):641-645.

[121] Miller RA, Nadon NL. Principles of animal use for gerontological research. J Gerontol Ser A Biol Sci Med Sci. 2000; 55(3):B117-B123.

[122] Palliyaguru DL, Moats JM, Di Germanio C, Bernier M, de Cabo R. Frailty index as a biomarker of lifespan and healthspan: Focus on pharmacological interventions. Mech Ageing Dev. 2019; 180:42-48.

[123] Kane AE, Howlett SE. Sex differences in frailty: Comparisons between humans and preclinical models. Mech Ageing Dev. 2021; 198:111546.

[124] Ohta Y, Fujii M, Takahashi S, Takano A, Nanki K, Matano M, et al. Cell-matrix interface regulates dormancy in human colon cancer stem cells. Nature. 2022; 608(7924):784-794.

[125] Lee S, Mendoza TR, Burner DN, Muldong MT, Wu CCN, Arreola-Villanueva C, et al. Novel dormancy mechanism of castration resistance in bone metastatic prostate cancer organoids. Int J Mol Sci. 2022; 23(6):3203.

[126] Richbourg NR, Irakoze N, Kim H, Peyton SR. Outlook and opportunities for engineered environments of breast cancer dormancy. Sci Adv. 2024; 10(10):eadl0165.

[127] Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, et al. Tumour evolution inferred by single-cell sequencing. Nature. 2011; 472(7341):90-94.

[128] Sun C, Wang A, Zhou Y, Chen P, Wang X, Huang J, et al. Spatially resolved multi-omics highlights cell-specific metabolic remodeling and interactions in gastric cancer. Nat Commun. 2023; 14(1):2692.

[129] Ståhl PL, Salmén F, Vickovic S, Lundmark A, Navarro JF, Magnusson J, et al. Visualization and analysis of gene expression in tissue sections by spatial transcriptomics. Science. 2016; 353(6294):78-82.

[130] Chen KH, Boettiger AN, Moffitt JR, Wang S, Zhuang X. Spatially resolved, highly multiplexed RNA profiling in single cells. Science. 2015; 348(6233):aaa6090.

[131] Rodriques SG, Stickels RR, Goeva A, Martin CA, Murray E, Vanderburg CR, et al. Slide-seq: A scalable technology for measuring genome-wide expression at high spatial resolution. Science. 2019; 363(6434):1463-1467.

[132] Buenrostro JD, Corces MR, Lareau CA, Wu B, Schep AN, Aryee MJ, et al. Integrated single-cell analysis maps the continuous regulatory landscape of human hematopoietic differentiation. Cell. 2018; 173(6):1535-1548.e16.

[133] Lee J, Hyeon DY, Hwang D. Single-cell multiomics: Technologies and data analysis methods. Exp Mol Med. 2020; 52(9):1428-1442.

[134] Giesen C, Wang HA, Schapiro D, Zivanovic N, Jacobs A, Hattendorf B, et al. Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry. Nat Methods. 2014; 11(4):417-422.

[135] Richman J, Dowsett M. Beyond 5 years: Enduring risk of recurrence in oestrogen receptor-positive breast cancer. Nat Rev Clin Oncol. 2019; 16(5):296-311.

[136] Colleoni M, Sun Z, Price KN, Karlsson P, Forbes JF, Thürlimann B, et al. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: Results from the international breast cancer study group trials I to V. J Clin Oncol. 2016; 34(9):927-935.

[137] Han HH, Lee SH, Kim BG, Lee JH, Kang S, Cho NH, et al. Estrogen receptor status predicts late-onset skeletal recurrence in breast cancer patients. Medicine. 2016; 95(8):e2909.

[138] Kim K, Marquez-Palencia M, Malladi S. Metastatic latency, a veiled threat. Front Immunol. 2019; 10:1836.